Trade Ligand Pharmaceuticals Incorpor - LGND CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 2.32
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.021596 %(-$4.32)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02160%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000626 %(-$0.13)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.00063%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.1
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021596 %
  (-$4.32)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000626 %
  (-$0.13)

Key Stats

• Prev. Close: 289.19
• Open: 287.17
• 1-Year Change: 73.34%
• Day's Range: 284.32 - 288.15

Trade Ligand Pharmaceuticals Incorpor - LGND

About Ligand Pharmaceuticals Inc.

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company. The Company is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. It has partnerships and license agreements with approximately 140 pharmaceutical and biotechnology companies and 400 programs are in various stages of commercialization, development or research and are fully funded by its collaboration partners and licensees. Its technologies include OmniAb Technologies, Pelican Expression Technology Platform, Captisol Technology, HepDirect, LTP, BEPro Technology Platform, and SUREtechnology Platform. The OmniAb platform creates and screens diverse antibody pools and is designed to identify optimal antibodies. The Pelican Expression Technology is a scalable platform for recombinant protein production and is suited for complex, large-scale protein production. Captisol is a chemically modified cyclodextrin designed to optimize the stability of drugs.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Ligand Pharmaceuticals Inc. revenues increased 49% to $277.1M. Net income totaled $57.1M vs. loss of $3M. Revenues reflect Captisol segment increase of 49% to $164.3M, Milestone segment increase from $11.5M to $28.7M. Net Income reflects Gain (loss) from short-term investments decrease of 76% to $4M (expense), Other General and administrative decrease of 23% to $36.1M (expense).

Equity composition

Common Stock $.006 Par, 3/11, 33,333,3333 auth., 20,644,234 issd., less 1,118,222 shs in Treas. @ $42.3M. Insiders own 3.36%. IPO:11/92, 4.3M Class A shares @ $11 by Lehman Bros. FY'00 Q's are restated for SAB 101 adjustment. 9/05,Co. delisted from NASDAQ to OTC.11/10, 1-for-06 Reverse Stock split.